Collection
Latest updates from major conferences
This Experimental Hematology & Oncology and Journal of Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference.
Articles published in the collection have already gone through the systematic peer review process of the journal.
Articles (12 in this collection)
-
-
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Authors (first, second and last of 7)
-
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Authors (first, second and last of 11)
-
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting
Authors (first, second and last of 5)
-
The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice
Authors (first, second and last of 6)
-
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
Authors (first, second and last of 11)
-
Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system
Authors (first, second and last of 16)
-
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
Authors (first, second and last of 11)
-
-
-
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
Authors (first, second and last of 12)
-
